Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway

Sang Soo Cho, Leigh Christopher, Yuko Koshimori, Crystal Li, Anthony E. Lang, Sylvain Houle, Antonio P. Strafella

Research output: Contribution to journalArticle

Abstract

To date, the contribution of the nigropallidal pathway degeneration to Parkinson's disease (PD) motor symptoms has received little attention and is generally poorly understood in spite of solid evidence that the globus pallidus (GP) receives a dense neuronal projection from the substantia nigra. To explore the dopaminergic (DA) changes of the GP in PD, we measured the availability of vesicular monoamine transporter 2 (VMAT2) using [11C]DTBZ and positron emission tomography in 30 PD patients and 12 controls. PD patients were classified in two groups based on severity of disease. VMAT2 reduction was found to be significant in the external GP (GPe) regardless of the disease stage, while the internal GP (GPi) showed reduction only in more severe patients. Pallidal VMAT2 binding correlated with dopaminergic changes in the striatum, with the GPe showing a stronger association than GPi. Our findings showed DA terminals in the GPe and GPi may be differentially vulnerable in different stages of the disease, possibly playing a distinctive role in the development of motor complications with GPi DA deficiency contributing more to later-stage symptoms.

Original languageEnglish (US)
Pages (from-to)176-182
Number of pages7
JournalNeurobiology of Disease
Volume124
DOIs
StatePublished - Apr 2019

Keywords

  • Dopamine
  • Globus pallidus
  • Parkinson's disease
  • Positron emission tomography
  • Vesicular monoamine transporter type 2

ASJC Scopus subject areas

  • Neurology

Fingerprint Dive into the research topics of 'Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway'. Together they form a unique fingerprint.

  • Cite this